Cargando…

Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial

BACKGROUND AND PURPOSE: Proximal femur is a common site for metastasis, it has a significant impact on patient’s quality of life, and traditional treatment aims at protecting as much as possible from the femur. However, recent studies have demonstrated increased rate of complications and questioned...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelmonem, Ibrahim Mahmoud, Azmy, Sherif Ishak, EL Masry, Ayman Mohammad, el ghazawy, Ahmed k, kotb, Ahmed sayed, Bassiony, Ayman Abdelaziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360160/
https://www.ncbi.nlm.nih.gov/pubmed/35152311
http://dx.doi.org/10.1007/s00068-021-01875-x
_version_ 1784764291777298432
author Abdelmonem, Ibrahim Mahmoud
Azmy, Sherif Ishak
EL Masry, Ayman Mohammad
el ghazawy, Ahmed k
kotb, Ahmed sayed
Bassiony, Ayman Abdelaziz
author_facet Abdelmonem, Ibrahim Mahmoud
Azmy, Sherif Ishak
EL Masry, Ayman Mohammad
el ghazawy, Ahmed k
kotb, Ahmed sayed
Bassiony, Ayman Abdelaziz
author_sort Abdelmonem, Ibrahim Mahmoud
collection PubMed
description BACKGROUND AND PURPOSE: Proximal femur is a common site for metastasis, it has a significant impact on patient’s quality of life, and traditional treatment aims at protecting as much as possible from the femur. However, recent studies have demonstrated increased rate of complications and questioned the need for long stem in this high-risk group. Our purpose is to determine whether standard-length femoral stem is noninferior to long femoral stem in the treatment of proximal femoral metastasis. PATIENTS AND METHODS: Between 2019 and 2021, we prospectively included 24 patients with proximal femoral metastasis leading either to impending or pathological fractures (5 and 19 cases, respectively). We included patients with lesions due to metastasis, lymphoma, or multiple myeloma. Patients were quasi-randomized based on their order of presentation into two groups based on the femoral stem length, cemented standard (group 1) and long (group 2) femoral stem. Oncological complications, survival, stem complications, and functional outcomes were recorded and analyzed using SPSS 25. RESULTS: 24 patients were included in the final analysis, 13 case in group 1 and 11 in group 2, and mean age 57.6 years. Mean follow-up duration was 10 months, and 11 patients died of the whole-study population with mean survival of (10.85 ± 2.23, 8.82 ± 3.6) months in group 1, 2, respectively. The complication rate was higher in the standard group; however, this difference did not reach statistical significance. No difference was found between study groups regarding functional outcomes, except for VAS at 6 months which was higher in standard group. CONCLUSION: We believe that the ubiquitous use of long stem in the management of proximal femoral metastasis should be questioned considering the expected patient survival and low rate of complications associated with the use of standard stem. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT04660591.
format Online
Article
Text
id pubmed-9360160
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93601602022-08-10 Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial Abdelmonem, Ibrahim Mahmoud Azmy, Sherif Ishak EL Masry, Ayman Mohammad el ghazawy, Ahmed k kotb, Ahmed sayed Bassiony, Ayman Abdelaziz Eur J Trauma Emerg Surg Original Article BACKGROUND AND PURPOSE: Proximal femur is a common site for metastasis, it has a significant impact on patient’s quality of life, and traditional treatment aims at protecting as much as possible from the femur. However, recent studies have demonstrated increased rate of complications and questioned the need for long stem in this high-risk group. Our purpose is to determine whether standard-length femoral stem is noninferior to long femoral stem in the treatment of proximal femoral metastasis. PATIENTS AND METHODS: Between 2019 and 2021, we prospectively included 24 patients with proximal femoral metastasis leading either to impending or pathological fractures (5 and 19 cases, respectively). We included patients with lesions due to metastasis, lymphoma, or multiple myeloma. Patients were quasi-randomized based on their order of presentation into two groups based on the femoral stem length, cemented standard (group 1) and long (group 2) femoral stem. Oncological complications, survival, stem complications, and functional outcomes were recorded and analyzed using SPSS 25. RESULTS: 24 patients were included in the final analysis, 13 case in group 1 and 11 in group 2, and mean age 57.6 years. Mean follow-up duration was 10 months, and 11 patients died of the whole-study population with mean survival of (10.85 ± 2.23, 8.82 ± 3.6) months in group 1, 2, respectively. The complication rate was higher in the standard group; however, this difference did not reach statistical significance. No difference was found between study groups regarding functional outcomes, except for VAS at 6 months which was higher in standard group. CONCLUSION: We believe that the ubiquitous use of long stem in the management of proximal femoral metastasis should be questioned considering the expected patient survival and low rate of complications associated with the use of standard stem. CLINICALTRIALS.GOV REGISTRATION NUMBER: NCT04660591. Springer Berlin Heidelberg 2022-02-13 2022 /pmc/articles/PMC9360160/ /pubmed/35152311 http://dx.doi.org/10.1007/s00068-021-01875-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Abdelmonem, Ibrahim Mahmoud
Azmy, Sherif Ishak
EL Masry, Ayman Mohammad
el ghazawy, Ahmed k
kotb, Ahmed sayed
Bassiony, Ayman Abdelaziz
Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title_full Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title_fullStr Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title_full_unstemmed Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title_short Cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
title_sort cemented long versus standard femoral stem in proximal femoral metastasis: a noninferiority single-blinded quasi-randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360160/
https://www.ncbi.nlm.nih.gov/pubmed/35152311
http://dx.doi.org/10.1007/s00068-021-01875-x
work_keys_str_mv AT abdelmonemibrahimmahmoud cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial
AT azmysherifishak cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial
AT elmasryaymanmohammad cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial
AT elghazawyahmedk cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial
AT kotbahmedsayed cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial
AT bassionyaymanabdelaziz cementedlongversusstandardfemoralsteminproximalfemoralmetastasisanoninferioritysingleblindedquasirandomizedclinicaltrial